Hydrocodone
| Evidence Level: L4 | Predicted Indications: 1 |
Table of Contents
- Hydrocodone
- Pharmacist Assessment Report
- Hydrocodone: From Allergic Rhinitis and Upper Respiratory Conditions to Nasal Cavity Disease
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Hydrocodone: From Allergic Rhinitis and Upper Respiratory Conditions to Nasal Cavity Disease
One-Sentence Summary
Hydrocodone is an opioid originally associated with symptom relief in upper respiratory conditions such as allergic rhinitis, pharyngitis, and the common cold. The TxGNN model predicts it may be effective for nasal cavity disease, but there are 0 clinical trials and only 1 publication (a case report describing harm from misuse), so the evidence is very weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, vasomotor rhinitis, pharyngitis, common cold, rhinitis, nasopharyngitis (the Canadian licence records contain no indication text) |
| Predicted New Indication | Nasal cavity disease |
| TxGNN Prediction Score | 0.9988 |
| Evidence Level | L4 |
| Canada Market Status | Marketed (marketed DINs: 1 of 2; dormant: 1) |
| Number of DINs | 2 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Hydrocodone is an opioid with known antitussive activity, and it is already linked to upper respiratory conditions such as rhinitis, pharyngitis, and the common cold. Mechanistically, it may relieve cough or symptoms associated with these conditions.
The high prediction score (0.9988) most likely reflects the network proximity of hydrocodone to those approved upper-respiratory indications, rather than a validated treatment effect. Symptom relief in upper-airway inflammation does not support treating structural nasal cavity disease.
The only supporting publication reports that intranasal abuse of hydrocodone-acetaminophen caused necrosis of the nasal cavity and pharynx. This is drug-induced harm to nasal tissue, not therapeutic benefit, so the available evidence points toward a safety concern rather than repurposing potential.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 22965281 | 2012 | Case report | The Laryngoscope | Intranasal abuse of hydrocodone-acetaminophen was associated with necrosis of the nasal cavity and pharynx. This shows tissue damage, not a therapeutic effect. |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02324253 | PDP-HYDROCODONE | Not specified | Not specified |
| 02230769 | DALMACOL | Not specified | Not specified |
Safety Considerations
- Contraindications flagged in the knowledge graph (not label text): The drug-disease network links hydrocodone to a wide range of conditions where caution or avoidance may apply, including:
- Respiratory: chronic obstructive pulmonary disease
- Liver and kidney: liver failure, liver disease, kidney disease
- Gastrointestinal: pancreatitis, peptic and gastric ulcer, inflammatory bowel disease, gallbladder disease
- Neurological and substance-related: epilepsy, substance abuse/dependence
- Cardiovascular: hypertension, hypotension, coronary artery disease, myocardial infarction
- Endocrine and metabolic: hypothyroidism, myxedema, diabetes mellitus, diabetic ketoacidosis
- Bleeding and blood disorders: thrombocytopenia, hemophilia, blood coagulation disease
- Other: benign prostatic hyperplasia, gout, rhabdomyolysis
- Drug Interactions: 525 known interactions were identified. Major-level examples include:
- Opioids and opioid-related agents: morphine (including liposomal), naltrexone, alvimopan
- Enzyme-interacting drugs: clarithromycin, cimetidine, bupropion, clotrimazole, dexamethasone, aprepitant
- Moderate-level examples include anticholinergics (atropine, hyoscyamine, clidinium), loperamide, metoclopramide, naloxone, and dronabinol.
- Misuse risk: The literature shows that intranasal misuse can cause serious tissue necrosis. Opioid-related risks such as respiratory depression and dependence also need careful assessment.
Please also refer to the package insert for label-based warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a high model score. The single publication is a case report of harm, not benefit, and there are no clinical trials. Combined with the opioid safety profile and extensive interaction burden, the evidence does not justify advancing nasal cavity disease as a repurposing target.
To proceed, the following is needed:
- Mechanism of action data to establish a plausible therapeutic link
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Clinical or observational evidence showing therapeutic benefit, not just harm from misuse
- Approved indication text, dosage forms, and routes for the two Canadian authorizations
- A clear distinction between genuine new uses and extensions of existing labelled indications (especially for acute laryngopharyngitis)
- A safety and misuse-risk assessment covering dependence, respiratory depression, and interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.